[HTML][HTML] Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis …
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …
[PDF][PDF] Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and …
GR Mohyuddin, M Aziz, A Britt, L Wade, W Sun… - 2020 - researchgate.net
Background: PARP inhibitors (PARPi) have recently been approved for various
malignancies based on the results of several clinical trials. However, these trials have mostly …
malignancies based on the results of several clinical trials. However, these trials have mostly …
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and …
GR Mohyuddin, M Aziz, A Britt, L Wade… - BMC …, 2020 - pubmed.ncbi.nlm.nih.gov
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and …
GR Mohyuddin, M Aziz, A Britt, L Wade, W Sun… - 2020 - kuscholarworks.ku.edu
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and …
GR Mohyuddin, M Aziz, A Britt, L Wade, W Sun… - BMC Cancer, 2020 - europepmc.org
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …
[HTML][HTML] Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis …
GR Mohyuddin, M Aziz, A Britt, L Wade, W Sun… - BMC Cancer, 2020 - ncbi.nlm.nih.gov
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and …
GR Mohyuddin, M Aziz, A Britt, W Lee, W Sun… - BMC …, 2020 - search.proquest.com
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …
[引用][C] Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and …
GR Mohyuddin, M Aziz, A Britt, L Wade, W Sun… - BMC Cancer …, 2020 - jglobal.jst.go.jp
Similar response rates and survival with PARP inhibitors for patients with solid tumors
harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic …
harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic …
[HTML][HTML] Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis …
GR Mohyuddin, M Aziz, A Britt, L Wade… - BMC …, 2020 - bmccancer.biomedcentral.com
PARP inhibitors (PARPi) have recently been approved for various malignancies based on
the results of several clinical trials. However, these trials have mostly recruited patients with …
the results of several clinical trials. However, these trials have mostly recruited patients with …
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and …
GR Mohyuddin, M Aziz, A Britt, L Wade, W Sun… - BMC Cancer, 2020 - go.gale.com
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …